Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Fengqi Fang"'
Autor:
Zhen Wang, Zining Jin, Huanrui Zhang, Guiying Xu, Dianlong Zhang, Fengqi Fang, Hua Xing, Jia Wang, Baoliang Guo, Guolian Zhu, Yongzhi Liu, Jieqing Li, Zhengang Cai, Liang Sun, Yuting Zhang, Tianyang Zhou, Chang Liu, Baosen Zhou, Feng Jin, Yan Zhang, Dong Song, Bo Chen, Sihan Zhou, Xiuyuan Hao
Publikováno v:
Chinese Medical Journal, Vol 137, Iss 14, Pp 1756-1758 (2024)
Externí odkaz:
https://doaj.org/article/cb8f3cc31d6a4f32a02244576a178559
Publikováno v:
Cancer Control, Vol 31 (2024)
Background Male breast cancer (MBC) represents a rare subtype of breast cancer, with limited prognostic factor studies available. The purpose of this research was to develop a unique nomogram for predicting MBC patient overall survival (OS) and breas
Externí odkaz:
https://doaj.org/article/c2cef395028b48df82103b16ed81c581
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundBreast cancer (BC) is one of the most common cancers worldwide. The inevitability of drug resistance to initial anti-HER-2 therapy necessitates the emergence of second-line anti-HER-2 drugs which exhibit a promising outlook. Consequently, i
Externí odkaz:
https://doaj.org/article/762dd4d5e51044a19e4be0c7e8706e3c
Autor:
Yang Li, Jingjiao Zhang, Zhengang Cai, Xue Gao, Lina Zhang, Zhi Lu, Xiaojie Wang, Peiyao Yu, Jia Li, Fengqi Fang
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Background/aimHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with a higher risk of metastasis and poorer overall survival (OS) due to HER2 gene overexpression/amplification. Although anti-HER2 targeted therapy ha
Externí odkaz:
https://doaj.org/article/a21bc32c89bb4d7bbe6c63c4459b0348
Autor:
Lanxin Zhang, Siwen Sun, Xiaotian Zhao, Jingwen Liu, Yang Xu, Lingzhi Xu, Chen Song, Na Li, Jing Yu, Shanshan Zhao, Peiyao Yu, Fengqi Fang, Jiping Xie, Xuening Ji, Ruoying Yu, Qiuxiang Ou, Zuowei Zhao, Man Li
Publikováno v:
Molecular Oncology, Vol 16, Iss 20, Pp 3689-3702 (2022)
Approximately 30% of breast cancer (BC) patients suffer from disease relapse after definitive treatment. Monitoring BC at baseline and disease progression using comprehensive genomic profiling would facilitate the prediction of prognosis. We retrospe
Externí odkaz:
https://doaj.org/article/d8a35b9fa8fb4c60be1f45ee129fa64e
Publikováno v:
Journal of Cardiovascular Development and Disease, Vol 9, Iss 11, p 372 (2022)
Cardiotoxicity is one of the major side effects of anti-cancer therapy affecting the overall prognosis of patients and possibly leading to the discontinuation of chemotherapy. Traditional cardiovascular tests such as electrocardiography and transthor
Externí odkaz:
https://doaj.org/article/f801a7dd29084fa58a1f3b96007381a1
Autor:
Yunsong Wang, Haichen Lv, Daobo Li, Cheng Chen, Guangming Gu, Yang Sun, Xiaolei Yang, Ying Liu, Fengqi Fang, Jiwei Liu, Gary Tse, Yunlong Xia
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Background: Venous thromboembolism (VTE) is a common complication in patients with cancer. Direct oral anticoagulants (DOACs) have been proved to be effective on anticoagulation therapy in many diseases. However, the efficacy and the safety of DOACs
Externí odkaz:
https://doaj.org/article/9966329867df40ab89280eb0ef9bacc4
Publikováno v:
Seminars in Diagnostic Pathology. 40:88-94
Publikováno v:
Journal of the American Society of Cytopathology. 11:S33
Autor:
Hui-Hua Li, Yunlong Xia, Ying Liu, Xiaolei Yang, Fengqi Fang, Jiwei Liu, Fei Liu, Tesfaldet Habtemariam Hidru, Yajuan Lin, Ruiyuan Gao
Publikováno v:
Journal of Hypertension
Background Recent studies have reported the prevalence of cardiovascular diseases (CVDs) among cancer patients following the use of the vascular endothelial growth factor (VEGF) signaling inhibitors. However, data for patients with a history of cance